American Surgical Association Annual Meeting
Search Meeting Site Only
 
Main ASA Website
Current Meeting Home
Final Program
Past & Future Meetings

 

 

Back to 2015 Annual Meeting Program


Prospective Randomized Double Blinded Trial Comparing Two Anti-mrsa Agents With Supplemental Coverage To Cefazolin Prior To Lower Extremity Revascularization.
patrick A stone*, ali abuRahma, Stephen Hass*, albeir Mousa*, Asmita Modak*, Mary Emmett*, James Campbell*, Aravinda Nanjundappa*, Mohit Srivastiva*
WVU, charleston, WV

Current antibiotic prophylaxis for vascular procedures includes a first generation cephalosporin No changes in recommendations have occurred despite changes in reports of incidence of MRSA related surgical site infections. Does supplemental anti-MRSA prophylactic coverage provide a significant reduction in gram + or MRSA infections?.
Methods: Single center prospective double blinded randomized study of patients undergoing lower extremity vascular procedures from 2010-2014. 178 patients evaluable at 90 days for surgical site infection. Infections were categorized as early infections <90 days of the index procedure and late after 90days.
Results: Early vascular Surgical site infection occurred in 6(7.06%) of patients in the Vancomycin arm, and 11(11.83%) in the Daptomycin arm. (p=.27). Gram positive related infections and MRSA infections occurred in 0%/0% of Vancomycin patients and 2(2.15%)/7(7.53%) of Daptomycin patients respectively (p<0.01 & p=0.49). Readmissions related to surgical site infections occurred in 4(4.71%) in the Vancomycin group and 11(11.8%) in the Daptomycin group (p=0.083). Patients undergoing operative exploration occurred in 4(4.71%) in the Vancomycin group and 10(10.75%) of the Daptomycin group (p=.128). Late infections occurred in 2 patients in both arms. Median hospital charges related to readmissions related to surgical site infections were in the Vancomycin supplemented and Daptomycin supplemented patients was 45,450 dollars and 51,182 dollars respectively. (p=0.79)
Conclusion: Vancomycin supplemental prophylaxis appears to reduce the incidence of gram positive infection compared to adding supplemental Daptomycin prophylaxis. The Incidence of MRSA related surgical site infection is low with the addition of either anti-MRSA agents compared to historical incidence of MRSA related infection.


Back to 2015 Annual Meeting Program


© 2022 American Surgical Association. All Rights Reserved. Privacy Policy.